Which Tests Should Be Done Before Starting A Weight-Loss Injection?

There is no single mandatory test package that applies to everyone before starting a weight-loss injection. Height, weight, body mass index, blood pressure, medical history and current medicines are reviewed first, and laboratory tests are selected according to symptoms, health conditions and the medicine being considered.

Blood glucose or HbA1c, kidney and liver function, lipid profile and a complete blood count may commonly be considered. Thyroid tests, pregnancy testing, eye examination, gallbladder imaging and cardiac investigations are not routine for everyone and are requested according to medical history and examination. NICE states that blood pressure, lipid profile, HbA1c, blood glucose, kidney and liver function, full blood count and thyroid tests may be considered according to clinical need.

Why Is Assessment Needed Before Treatment?

A weight-loss injection is not simply a cosmetic product. It is a prescription treatment that may affect appetite, stomach emptying and blood glucose. The clinician should therefore assess whether the person is suitable, identify accompanying conditions and consider the risk of adverse effects.

Testing is not performed only to give “permission” to use the medicine. It also helps identify diabetes, thyroid disease, fatty liver or medicines that may contribute to weight gain, record baseline values for later comparison and create a monitoring plan.

Which Information Is Reviewed During the First Consultation?

A detailed medical history should be taken before laboratory testing. Starting treatment according only to weight and body mass index is not safe.

The first assessment may include:

• When weight gain began
• Previous nutrition and medicine treatments
• Diabetes, hypertension, cholesterol and sleep apnea
• Previous pancreatitis or gallstones
• Kidney and liver conditions
• Delayed stomach emptying or serious gastrointestinal symptoms
• Current medicines and supplements
• Insulin and other glucose-lowering treatments
• Pregnancy, breastfeeding and pregnancy plans
• Eating disorders or significant mental health concerns
• Personal or family conditions that may create medicine-specific contraindications

NICE recommends reviewing accompanying conditions, medicines, treatments that may cause weight gain and pregnancy plans at baseline.

Why Are Height, Weight, Body Mass Index and Waist Circumference Measured?

Body mass index is calculated using height and weight. It helps classify overweight or obesity and assess whether the person meets the authorised criteria for the medicine.

Waist circumference or waist-to-height ratio may help assess metabolic risk related to abdominal fat. These measurements do not determine treatment alone and should be interpreted with diabetes, blood pressure, sleep apnea and other health conditions.

Baseline measurements also provide a reference for evaluating treatment. Changes in waist circumference, blood pressure and metabolic values may be monitored alongside weight.

Why Are Fasting Glucose and HbA1c Checked?

Fasting glucose and HbA1c help assess whether previously unrecognised prediabetes or type 2 diabetes is present. HbA1c provides information about average glucose over the previous few months.

These tests are especially relevant when there is:

• A family history of diabetes
• Increased waist circumference
• Previous gestational diabetes
• Frequent thirst and urination
• Insulin resistance or polycystic ovary syndrome
• Previous borderline glucose results

When a person uses insulin or a sulfonylurea, adding a weight-loss injection may increase hypoglycemia risk. Existing diabetes treatment should be reviewed and doses adjusted when necessary.

Why May Kidney Function Tests Be Requested?

Creatinine and estimated glomerular filtration rate may be used to assess kidney function. Some GLP-1-based medicines do not directly damage the kidneys, but dehydration caused by nausea, vomiting or diarrhoea may worsen kidney function.

Testing is particularly important in people with:

• Known kidney disease
• Older age
• Diuretic use
• Recurrent vomiting or dehydration risk
• Diabetes or hypertension

When severe vomiting, diarrhoea or difficulty drinking develops during treatment, kidney function may need reassessment even when baseline results were normal.

Why Are Liver Function Tests Reviewed?

ALT, AST and other liver tests may provide information about fatty liver, liver injury or accompanying disease. Obesity and type 2 diabetes may occur with metabolic fatty liver disease.

A mild enzyme elevation does not automatically mean that the medicine cannot be used. The cause should be assessed and the official product information considered. People with severe liver disease require specialist planning.

Why Are Cholesterol and Triglycerides Important?

Total cholesterol, LDL, HDL and triglycerides help assess cardiovascular risk. Weight-management planning should address the complete metabolic risk profile rather than weight alone.

Finding high cholesterol or triglycerides does not mean that a weight-loss injection is sufficient by itself. Nutrition, physical activity and lipid-lowering treatment when needed should be planned separately. NICE recommends considering a lipid profile according to clinical need.

Why May a Complete Blood Count Be Requested?

A complete blood count may help assess anaemia, signs of infection and changes in blood cells. It may be particularly relevant in people with heavy menstrual bleeding, restrictive diets, previous stomach or intestinal surgery or marked fatigue.

When anaemia or nutritional deficiency is present, the cause may need assessment before beginning a medicine that reduces appetite. A complete blood count is not mandatory for everyone but may be included according to medical history.

Does Everyone Need a Thyroid Test?

TSH and, when required, free T4 may be assessed when weight gain occurs with thyroid symptoms or known thyroid disease. Fatigue, feeling cold, constipation, dry skin, menstrual irregularity or neck enlargement may increase the need for testing.

However, it cannot be said that everyone starting a weight-loss injection automatically needs a comprehensive thyroid panel, ultrasound or calcitonin test. These investigations are selected according to medical history, examination and medicine-specific warnings.

A personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 may be an important contraindication or warning for certain products. The clinician should review the official information for the product being considered.

When Is a Pregnancy Test Needed?

Pregnancy status should be assessed when pregnancy is possible. GLP-1 and similar weight-management medicines are not recommended during pregnancy.

Testing may be considered when there is:

• A delayed menstrual period
• Unprotected intercourse
• Irregular periods that make pregnancy difficult to exclude
• A near-term pregnancy plan
• Suspected pregnancy

The time required between stopping treatment and attempting pregnancy varies between active ingredients. Semaglutide and tirzepatide, for example, do not have identical discontinuation periods. Medicine-specific planning is required.

Are Amylase and Lipase Routinely Required?

There is no single rule requiring pancreatic enzymes as routine baseline tests for everyone. A clinician may request additional assessment when there is previous pancreatitis, recurrent unexplained abdominal pain or pancreatic disease.

Severe persistent abdominal pain that may radiate to the back, with nausea or vomiting during treatment, requires urgent assessment for pancreatitis. The clinician should decide whether the medicine should be continued. The Medicines and Healthcare Products Regulatory Agency advises vigilance for pancreatitis symptoms with GLP-1 medicines.

Does Everyone Need a Gallbladder Ultrasound?

A gallbladder ultrasound is not mandatory for everyone. Imaging may be considered in people with previous gallstones, gallbladder inflammation or right-upper abdominal pain.

Rapid weight loss may increase gallstone risk, and some weight-management medicines are associated with gallbladder problems. Severe right-upper abdominal pain, fever, jaundice or repeated vomiting require medical assessment.

Who May Need a Diabetic Eye Examination?

In people with type 2 diabetes and diabetic retinopathy, rapid improvement in glucose may temporarily affect eye findings. The eye specialist and diabetes team should be informed when retinopathy is already known.

Eye examination is not routinely required for everyone starting treatment. However, assessment may be needed in people with long-standing diabetes, visual symptoms or overdue retinal screening.

Are Cardiac Tests or an ECG Required?

An ECG, echocardiogram or advanced cardiology testing is not routine for everyone. When chest pain, palpitations, fainting, known heart disease or significant cardiovascular risk is present, ECG and cardiology assessment may be requested.

Blood pressure and pulse should be measured at baseline. Because an increase in heart rate may occur with some medicines, pulse may also be reviewed during follow-up.

The cause of chest pain, serious shortness of breath or fainting should be assessed before weight-management treatment begins.

May a Sleep Test Be Needed?

A sleep-apnea assessment may be needed when loud snoring, witnessed breathing pauses, morning headache or excessive daytime sleepiness is present. Sleep apnea is associated with obesity and may influence the weight-management plan.

A sleep test is not mandatory before every weight-loss injection. An at-home sleep test or laboratory study may be arranged according to symptoms and clinical risk.

Which Tests Are Not Required for Everyone?

Extensive test lists shared online are not necessary for every patient. The following should be requested only when there is a clinical reason:

• Detailed hormone panels
• Insulin levels and insulin-resistance calculations
• Thyroid ultrasound
• Calcitonin
• Amylase and lipase
• Gallbladder ultrasound
• Cortisol testing
• ECG or echocardiography
• Sleep testing
• Broad vitamin and mineral panels

Unnecessary tests may increase cost and cause anxiety because of clinically insignificant variations. Missing genuinely necessary tests may also make treatment less safe. The investigation list should therefore be personalised.

Can the Medicine Be Started Immediately When Tests Are Normal?

Normal laboratory results do not automatically mean that the medicine is appropriate. Body mass index, weight history, current medicines, pregnancy, gastrointestinal conditions and product-specific contraindications must also be reviewed.

When treatment is selected, the starting dose and escalation plan are determined. The person should understand how to manage adverse effects, which symptoms require stopping treatment and when the first review will take place.

Obtaining medicine online or from non-prescription sources is not safe. Official authorities recommend using GLP-1 medicines only after healthcare-professional assessment and through reliable medicine-supply channels.

Which Values Are Followed After Treatment Begins?

Monitoring frequency depends on health conditions, the medicine and adverse effects. It is not necessary to repeat every blood test at each appointment.

Follow-up may include:

• Changes in weight and waist circumference
• Nausea, vomiting, diarrhoea or constipation
• Adequate fluid and protein intake
• Blood pressure and pulse
• Blood glucose in people with diabetes
• Kidney and liver function
• Gallbladder and pancreatitis symptoms
• Dose requirements of other medicines
• Mood and eating behaviour
• Whether treatment remains sustainable

NICE recommends regular assessment of effectiveness and tolerability and reconsidering the plan when response is insufficient or significant adverse effects occur.

Plan an Online Endocrinology Consultation With Happ Health

With our “Health Everywhere, for Everyone, Always” approach, we believe that weight-loss injection treatment should be supported by a safe baseline assessment and regular monitoring rather than only the issuing of a prescription.

Through Happ Health, you can arrange an Online Endocrinology Doctor consultation to review your weight and medical history, current medicines, available laboratory results and suitability for treatment. The endocrinologist may determine which tests are necessary according to personal risk and guide medicine, nutrition, physical activity or another treatment approach.

Preparing recent laboratory reports, a complete medicine list, previous weight-management treatments and available imaging reports before the consultation may make the assessment easier. An in-person examination or additional tests may be recommended when required.

Do not wait for an online review when severe persistent abdominal pain, repeated vomiting, inability to drink, fainting, jaundice or rapidly worsening general health occurs.

This content is intended for general information. Test selection, medicine suitability, dose escalation and monitoring must be determined individually by a physician.

References

• Republic of Türkiye Ministry of Health, General Directorate of Public Health. Obesity.
  https://hsgm.saglik.gov.tr/tr/obezite.html
• Republic of Türkiye Ministry of Health Electronic Library. Clinical Guideline for Obesity and Diabetes in Primary Healthcare.
  https://ekutuphane.saglik.gov.tr/Home/GetDocument/729
• National Institute for Health and Care Excellence. Initial Assessment and Monitoring for Tirzepatide.
  https://www.nice.org.uk/guidance/ta1026/resources/a-practical-guide-to-using-medicines-to-manage-overweight-and-obesity-15299628589/chapter/Prescribing-reviewing-and-stopping-tirzepatide
• National Institute for Health and Care Excellence. Initial Assessment Checklist.
  https://www.nice.org.uk/guidance/ta1026/resources
• Medicines and Healthcare Products Regulatory Agency. GLP-1 Medicines for Weight Loss and Diabetes.
  https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know
• Medicines and Healthcare Products Regulatory Agency. Updated Guidance on GLP-1 Medicines and Pancreatitis.
  https://www.gov.uk/government/news/mhra-updates-guidance-for-glp-1-prescribers-and-patients
• European Medicines Agency. Wegovy.
  https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
• United States Food and Drug Administration. Semaglutide Prescribing Information.
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf